SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (84)12/15/1997 11:55:00 AM
From: Pseudo Biologist  Read Replies (1) of 416
 
Mike, according to Morgan Stanley these were the expected milestones:

4Q97 BLA submission of MEDI-493 (anti-RSV)
4Q97 Ex-US marketing of MEDI-493 : this was the Abbott deal
4Q97 complete phase II trials of BTI-322 for graft vs. host
4Q97 MEDI-507 (transpl. drug) data available from phase I trial
4Q97 MEDI-507 start placebo controlled, blinded phase I/II in GvHD

...

The recent deal with SmithKline was not expected when that report was written (early October). Yep, this is a hot one.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News